» Articles » PMID: 11181370

Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus Aureus Infection

Overview
Specialty Pharmacology
Date 2001 Feb 22
PMID 11181370
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Daptomycin is a lipopeptide antibiotic with activity against gram-positive bacteria, including Staphylococcus aureus. We defined the pharmacodynamic parameters that determine the activity of daptomycin for S. aureus using in vitro methods and the Craig (W. A. Craig, J. Redington, and S. C. Ebert, J. Antimicrob. Chemother. 27[Suppl. C]:29--40, 1991) neutropenic mouse thigh infection model. In Mueller-Hinton broth, the MICs for three S. aureus isolates were 0.1 to 0.2 microg/ml. In mouse serum, the MICs were 1.0 microg/ml. The protein binding of daptomycin was 90 to 92.5% in mouse serum. Single-dose intraperitoneal (i.p.) pharmacokinetic studies with infected mice showed a linear relationship between dose versus the maximum concentration of drug in serum and dose versus the area under the concentration-time curve (AUC). The serum half-life of daptomycin in infected mice was approximately 1.8 h. In single-dose, dose-ranging studies using mice, daptomycin showed a dose-response effect described by an inhibitory sigmoid E(max) (maximum effect) curve (r = 0.974; P << 0.001). The density of S. aureus in untreated controls was 8.26 log(10) CFU/g, and the E(max) was 3.97 log(10) CFU/g. The 50% effective dose (ED(50)) was 3.7 mg/kg of body weight i.p. and the stasis dose was 7.1 mg/kg. Dose fractionation studies at schedules of Q6h, Q12h, and Q24h, for total 24-h ED(30), ED(60), and ED(80) doses of 2.5, 5.6, and 15 mg/kg i.p., showed no difference in effect at each total 24-h dose level by schedule, indicating that the AUC/MIC ratio is the dynamically linked variable.

Citing Articles

PK/PD Analysis of High-Dose Daptomycin Use in the Treatment of Bone and Joint Infections: Data from a Real-World Setting.

Angelini J, Giuliano S, Russiani F, Lo Re F, Flammini S, Cadeo B Microorganisms. 2025; 13(2).

PMID: 40005671 PMC: 11858051. DOI: 10.3390/microorganisms13020304.


Safety of high-dose daptomycin in obese patients: a multicentric retrospective study.

Meireles V, Airaud C, Demay E, Cazanave C, Xuereb F, Lazaro P Eur J Clin Microbiol Infect Dis. 2025; .

PMID: 39992533 DOI: 10.1007/s10096-025-05065-0.


Population pharmacokinetics of intravenous daptomycin in critically ill patients: implications for selection of dosage regimens.

Wu J, Zheng X, Zhang L, Wang J, Lv Y, Xi Y Front Pharmacol. 2024; 15:1378872.

PMID: 38756382 PMC: 11096781. DOI: 10.3389/fphar.2024.1378872.


A machine learning approach to predict daptomycin exposure from two concentrations based on Monte Carlo simulations.

Codde C, Rivals F, Destere A, Fromage Y, Labriffe M, Marquet P Antimicrob Agents Chemother. 2024; 68(5):e0141523.

PMID: 38501807 PMC: 11064575. DOI: 10.1128/aac.01415-23.


Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation.

Lewis S, Jang S, Mueller B BMC Nephrol. 2023; 24(1):270.

PMID: 37710245 PMC: 10500909. DOI: 10.1186/s12882-023-03314-y.


References
1.
Huovinen P, Kotilainen P . In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria. Antimicrob Agents Chemother. 1987; 31(3):455-7. PMC: 174751. DOI: 10.1128/AAC.31.3.455. View

2.
Drusano G, Johnson D, Rosen M, Standiford H . Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993; 37(3):483-90. PMC: 187696. DOI: 10.1128/AAC.37.3.483. View

3.
Bilello J, Bauer G, Dudley M, Cole G, Drusano G . Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother. 1994; 38(6):1386-91. PMC: 188215. DOI: 10.1128/AAC.38.6.1386. View

4.
Woodworth J, Nyhart Jr E, Brier G, Wolny J, Black H . Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 1992; 36(2):318-25. PMC: 188435. DOI: 10.1128/AAC.36.2.318. View

5.
Forrest A, Nix D, Ballow C, Goss T, Birmingham M, Schentag J . Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37(5):1073-81. PMC: 187901. DOI: 10.1128/AAC.37.5.1073. View